Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seqirus QIV vs Comparator QIV in Pediatric Population
NCT02914275Phase 3Completed
- Sponsor
- CSL Seqirus
- Start
- Sep 2016
- Primary completion
- Mar 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of influenza B virus B/Brisbane/46/2015 antigen (propiolactone inactivated) in influenza (4 cohorts), sponsored by CSL Seqirus. Primary endpoints: Geometric Mean Titer Ratio of Each Virus Strain and Difference in Seroconversion Rate for Each Virus Strain. Started Sep 2016; status: completed.
02
Drugs
influenza B virus B/Brisbane/46/2015 antigen (propiolactone inactivated)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02914275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02914275.